RMP1-14 is an IgG-like immunoglobulin antibody against mouse PD-1 that can block PD-1/PD-L1 signaling; its isotype control antibody is Mouse IgG2a kappa, Isotype Control.

PD-1/PD-L1:4.05 μg/mL, PD-1/PD-L1:1.99 μg/mL

Mice were subcutaneously injected with MC38 (1 × 106) or B16-hCXCR4 (5 × 105). After two weeks, tumors bearing mice were intraperitoneally (ip) treated with murine anti-PD-1 [RMP1–14] (5 mg/kg, twice week for 2 weeks), Pep R (2 mg/kg, 5 days per week for 2 weeks), or both agents.The results indicate that the combined treatment, Pep R plus anti-PD-1, resulted in a 2.67-fold reduction in MC38 Relative Tumor Volume (RTV) (p = 0.038), while neither anti-PD-1 nor Pep R alone significantly affected tumor growth[2].